HealthEquity saw an improvement in its IBD SmartSelect Composite Rating Friday, from 94 to 96.
The upgrade means the stock currently tops 96% of all other stocks in terms of key performance metrics and technical strength.
HealthEquity is currently extended beyond a proper buy zone after breaking out from an 88.26 buy point in a consolidation.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock sports a 92 EPS Rating, meaning its recent quarterly and longer-term annual earnings growth tops 92% of all stocks.
Its Accumulation/Distribution Rating of B- shows moderate buying by institutional investors over the last 13 weeks.
The company reported a 30% earnings gain for Q3. Top line growth fell to 21%, down from 23% in the previous quarter.
HealthEquity holds the No. 2 rank among its peers in the Commercial Services-Outsourcing industry group. ExlService Holdings is the No. 1-ranked stock within the group.
